171 related articles for article (PubMed ID: 22562771)
21. Dynamics of {beta}-amyloid reductions in brain, cerebrospinal fluid, and plasma of {beta}-amyloid precursor protein transgenic mice treated with a {gamma}-secretase inhibitor.
Barten DM; Guss VL; Corsa JA; Loo A; Hansel SB; Zheng M; Munoz B; Srinivasan K; Wang B; Robertson BJ; Polson CT; Wang J; Roberts SB; Hendrick JP; Anderson JJ; Loy JK; Denton R; Verdoorn TA; Smith DW; Felsenstein KM
J Pharmacol Exp Ther; 2005 Feb; 312(2):635-43. PubMed ID: 15452193
[TBL] [Abstract][Full Text] [Related]
22. REVIEW: γ-Secretase inhibitors for the treatment of Alzheimer's disease: The current state.
Panza F; Frisardi V; Imbimbo BP; Capurso C; Logroscino G; Sancarlo D; Seripa D; Vendemiale G; Pilotto A; Solfrizzi V
CNS Neurosci Ther; 2010 Oct; 16(5):272-84. PubMed ID: 20560993
[TBL] [Abstract][Full Text] [Related]
23. TASTPM mice expressing amyloid precursor protein and presenilin-1 mutant transgenes are sensitive to γ-secretase modulation and amyloid-β₄₂ lowering by GSM-10h.
Hussain I; Harrison DC; Hawkins J; Chapman T; Marshall I; Facci L; Ahmed S; Brackenborough K; Skaper SD; Mead TL; Smith BB; Giblin GM; Hall A; Gonzalez MI; Richardson JC
Neurodegener Dis; 2011; 8(1-2):15-24. PubMed ID: 20689247
[TBL] [Abstract][Full Text] [Related]
24. Orally bioavailable and brain-penetrant pyridazine and pyridine-derived γ-secretase modulators reduced amyloidogenic Aβ peptides in vivo.
Huang Y; Li T; Eatherton A; Mitchell WL; Rong N; Ye L; Yang XJ; Jin S; Ding Y; Zhang J; Li Y; Wu Y; Jin Y; Sang Y; Cheng Z; Browne ER; Harrison DC; Hussain I; Wan Z; Hall A; Lau LF; Matsuoka Y
Neuropharmacology; 2013 Jul; 70():278-86. PubMed ID: 23485401
[TBL] [Abstract][Full Text] [Related]
25. Pharmacodynamics of atabecestat (JNJ-54861911), an oral BACE1 inhibitor in patients with early Alzheimer's disease: randomized, double-blind, placebo-controlled study.
Timmers M; Streffer JR; Russu A; Tominaga Y; Shimizu H; Shiraishi A; Tatikola K; Smekens P; Börjesson-Hanson A; Andreasen N; Matias-Guiu J; Baquero M; Boada M; Tesseur I; Tritsmans L; Van Nueten L; Engelborghs S
Alzheimers Res Ther; 2018 Aug; 10(1):85. PubMed ID: 30134967
[TBL] [Abstract][Full Text] [Related]
26. Acute gamma-secretase inhibition of nonhuman primate CNS shifts amyloid precursor protein (APP) metabolism from amyloid-beta production to alternative APP fragments without amyloid-beta rebound.
Cook JJ; Wildsmith KR; Gilberto DB; Holahan MA; Kinney GG; Mathers PD; Michener MS; Price EA; Shearman MS; Simon AJ; Wang JX; Wu G; Yarasheski KE; Bateman RJ
J Neurosci; 2010 May; 30(19):6743-50. PubMed ID: 20463236
[TBL] [Abstract][Full Text] [Related]
27. Robust Translation of γ-Secretase Modulator Pharmacology across Preclinical Species and Human Subjects.
Toyn JH; Boy KM; Raybon J; Meredith JE; Robertson AS; Guss V; Hoque N; Sweeney F; Zhuo X; Clarke W; Snow K; Denton RR; Zuev D; Thompson LA; Morrison J; Grace J; Berisha F; Furlong M; Wang JS; Lentz KA; Padmanabha R; Cook L; Wei C; Drexler DM; Macor JE; Albright CF; Gasior M; Olson RE; Hong Q; Soares HD; AbuTarif M; Ahlijanian MK
J Pharmacol Exp Ther; 2016 Jul; 358(1):125-37. PubMed ID: 27189974
[TBL] [Abstract][Full Text] [Related]
28. Therapeutic potential of gamma-secretase inhibitors and modulators.
Imbimbo BP
Curr Top Med Chem; 2008; 8(1):54-61. PubMed ID: 18220933
[TBL] [Abstract][Full Text] [Related]
29. Quantitative measurement of changes in amyloid-beta(40) in the rat brain and cerebrospinal fluid following treatment with the gamma-secretase inhibitor LY-411575 [N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide].
Best JD; Jay MT; Otu F; Ma J; Nadin A; Ellis S; Lewis HD; Pattison C; Reilly M; Harrison T; Shearman MS; Williamson TL; Atack JR
J Pharmacol Exp Ther; 2005 May; 313(2):902-8. PubMed ID: 15743924
[TBL] [Abstract][Full Text] [Related]
30. Reduction of Abeta levels in the Sprague Dawley rat after oral administration of the functional gamma-secretase inhibitor, DAPT: a novel non-transgenic model for Abeta production inhibitors.
El Mouedden M; Vandermeeren M; Meert T; Mercken M
Curr Pharm Des; 2006; 12(6):671-6. PubMed ID: 16472156
[TBL] [Abstract][Full Text] [Related]
31. CNS amyloid-β, soluble APP-α and -β kinetics during BACE inhibition.
Dobrowolska JA; Michener MS; Wu G; Patterson BW; Chott R; Ovod V; Pyatkivskyy Y; Wildsmith KR; Kasten T; Mathers P; Dancho M; Lennox C; Smith BE; Gilberto D; McLoughlin D; Holder DJ; Stamford AW; Yarasheski KE; Kennedy ME; Savage MJ; Bateman RJ
J Neurosci; 2014 Jun; 34(24):8336-46. PubMed ID: 24920637
[TBL] [Abstract][Full Text] [Related]
32. Discovery of novel triazolobenzazepinones as γ-secretase modulators with central Aβ42 lowering in rodents and rhesus monkeys.
Fischer C; Zultanski SL; Zhou H; Methot JL; Shah S; Hayashi I; Hughes BL; Moxham CM; Bays NW; Smotrov N; Hill AD; Pan BS; Wu Z; Moy LY; Tanga F; Kenific C; Cruz JC; Walker D; Bouthillette M; Nikov GN; Deshmukh SV; Jeliazkova-Mecheva VV; Diaz D; Michener MS; Cook JJ; Munoz B; Shearman MS
Bioorg Med Chem Lett; 2015 Sep; 25(17):3488-94. PubMed ID: 26212776
[TBL] [Abstract][Full Text] [Related]
33. BACE1 Dynamics Upon Inhibition with a BACE Inhibitor and Correlation to Downstream Alzheimer's Disease Markers in Elderly Healthy Participants.
Timmers M; Barão S; Van Broeck B; Tesseur I; Slemmon J; De Waepenaert K; Bogert J; Shaw LM; Engelborghs S; Moechars D; Mercken M; Van Nueten L; Tritsmans L; de Strooper B; Streffer JR
J Alzheimers Dis; 2017; 56(4):1437-1449. PubMed ID: 28157093
[TBL] [Abstract][Full Text] [Related]
34. BACE1 Inhibitor Lanabecestat (AZD3293) in a Phase 1 Study of Healthy Japanese Subjects: Pharmacokinetics and Effects on Plasma and Cerebrospinal Fluid Aβ Peptides.
Sakamoto K; Matsuki S; Matsuguma K; Yoshihara T; Uchida N; Azuma F; Russell M; Hughes G; Haeberlein SB; Alexander RC; Eketjäll S; Kugler AR
J Clin Pharmacol; 2017 Nov; 57(11):1460-1471. PubMed ID: 28618005
[TBL] [Abstract][Full Text] [Related]
35. Selective amyloid-beta lowering agents.
Wolfe MS
BMC Neurosci; 2008 Dec; 9 Suppl 2(Suppl 2):S4. PubMed ID: 19090992
[TBL] [Abstract][Full Text] [Related]
36. Monoamine oxidase B is elevated in Alzheimer disease neurons, is associated with γ-secretase and regulates neuronal amyloid β-peptide levels.
Schedin-Weiss S; Inoue M; Hromadkova L; Teranishi Y; Yamamoto NG; Wiehager B; Bogdanovic N; Winblad B; Sandebring-Matton A; Frykman S; Tjernberg LO
Alzheimers Res Ther; 2017 Aug; 9(1):57. PubMed ID: 28764767
[TBL] [Abstract][Full Text] [Related]
37. gamma-Secretase as a therapeutic target in Alzheimer's disease.
Guardia-Laguarta C; Pera M; Lleó A
Curr Drug Targets; 2010 Apr; 11(4):506-17. PubMed ID: 20015011
[TBL] [Abstract][Full Text] [Related]
38. Quantitative assessment of Aβ peptide in brain, cerebrospinal fluid and plasma following oral administration of γ-secretase inhibitor MRK-560 in rats.
Wu G; Wu Z; Na S; Hershey JC
Int J Neurosci; 2015; 125(8):616-24. PubMed ID: 25567290
[TBL] [Abstract][Full Text] [Related]
39. The novel gamma secretase inhibitor N-[cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexyl]-1,1,1-trifluoromethanesulfonamide (MRK-560) reduces amyloid plaque deposition without evidence of notch-related pathology in the Tg2576 mouse.
Best JD; Smith DW; Reilly MA; O'Donnell R; Lewis HD; Ellis S; Wilkie N; Rosahl TW; Laroque PA; Boussiquet-Leroux C; Churcher I; Atack JR; Harrison T; Shearman MS
J Pharmacol Exp Ther; 2007 Feb; 320(2):552-8. PubMed ID: 17099072
[TBL] [Abstract][Full Text] [Related]
40. Gamma-secretase inhibitors for Alzheimer's disease: balancing efficacy and toxicity.
Barten DM; Meredith JE; Zaczek R; Houston JG; Albright CF
Drugs R D; 2006; 7(2):87-97. PubMed ID: 16542055
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]